Login / Signup

Acitretin treatment in antimalarial-refractory/intolerant discoid lupus erythematosus: A prospective, open-label, uncontrolled study.

Kulwadee LaosakulSiri ChiewchanvitMati ChuamanochanNapatra Tovanabutra
Published in: Lupus (2022)
Acitretin appears to be an effective treatment with acceptable safety profiles for antimalarial-refractory/intolerant DLE.
Keyphrases
  • open label
  • clinical trial
  • systemic lupus erythematosus
  • squamous cell carcinoma
  • study protocol
  • disease activity
  • phase ii
  • plasmodium falciparum